NCT01004718

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Detailed description

OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.

Conditions

• Lymphoma

Interventions

Type	Name	Description
RADIATION	Fludeoxyglucose F18	Undergo FDG PET/CT scans
PROCEDURE	Computed Tomography	Undergo FDG PET/CT scans
PROCEDURE	Positron emission tomography	Undergo FDG PET/CT scans

Timeline

• Start date: 2009-05-01
• Primary completion: 2013-07-01
• Completion: 2014-11-05
• First posted: 2009-10-30
• Last updated: 2021-05-18
• Results posted: 2021-05-18

Locations

1 site across 1 country: United States